Brenda Larkin - Concepedia

Author

Brenda Larkin

Also Known As

B. D. Larkin, Brenda D Larkin, Brenda D. Larkin, Brenda Larkin, Jennifer Cunningham, Justine Jones, Maria Burgos Florez, Pamela J. M. Costner, Vicki Barnett, William Duffy

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

National Institutes of Health National Institute of Allergy and Infectious Diseases Emmes (United States)Saint Louis University Emory University

About

Brenda Larkin is an author at National Institutes of Health specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	871
2	Immunology	10	10	871
3	Public Health	1	1	13
4	Allergy	1	1	94
5	Global Health	1	1	13

Brenda Larkin

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials Martin R. Gaudinski, Katherine V. Houser, Kaitlyn M. Morabito, The Lancet	2017	298
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial Julie E. Martin, Mark K. Louder, LaSonji A. Holman, Vaccine VaccinationVaccine DevelopmentMedicineImmunologyTherapeutic Vaccine	2008	271
Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses Richard A. Koup, Mario Roederer, Laurie Lamoreaux, PLoS ONE	2010	132
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study Martin R. Gaudinski, Emily E. Coates, Laura Novik, The Lancet VaccinationOpen-label Phase 1Vaccine TargetImmunologyAntiviral Drug Development	2019	123
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial Martin R. Gaudinski, Katherine V. Houser, Nicole A. Doria‐Rose, The Lancet HIV ImmunologyPharmacologyTherapeutic EfficacyAntibody ScreeningAntibody Engineering	2019	105
Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability Outcomes Grace Chen, Emily E. Coates, Sarah H. Plummer, JAMA	2020	103
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naïve and vaccinia-immune individuals Janie Parrino, Lewis McCurdy, Brenda Larkin, Vaccine VaccinationVaccinologyVaccine DevelopmentVaccinia AnkaraImmunology	2006	94
Modified Vaccinia Ankara: Potential as an Alternative Smallpox Vaccine Lewis McCurdy, Brenda Larkin, Jennifer E. Martin, Clinical Infectious Diseases VaccinationVaccinologyVaccine DevelopmentAllergyModified Vaccinia Ankara	2004	94
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial Tracy J. Ruckwardt, Kaitlyn M. Morabito, Emily Phung, The Lancet Respiratory Medicine VaccinationVaccine SafetyVaccine DevelopmentImmunologyVirology	2021	62
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial Melinda Hamer, Katherine V. Houser, Amelia R. Hofstetter, The Lancet VaccinationVaccine SafetyVaccine DevelopmentVaccine TargetImmunology	2023	62

Page 1